Important foundations laid in FY21 ahead of 2022 catalysts that shld accelerate commercial prospects for Angle’s #liquidbiopsy business, including potential FDA clearance of @Parsortix in #breastcancer & of 1st LDT for #ovariancancer. For more on $AGL see: https://www.trinitydelta.org/companies/angle/

We’ve reached another milestone w our 300th published report!

Visit our website for in-depth #healthcare & #lifesciences coverage on:
#AllergyTherapeutics @Parsortix @arecor_plc @avacta #FuturaMedical @hutchmed @MaxCyte_info @RedxPharma @scancellpharma
https://www.trinitydelta.org/company-pages/

FY21 results confirm #FuturaMedical cash runway beyond key value inflection points inc initial ex-US launches & potential US #MED3000 approval in Q123. Hint at Europe/UK commercial deal w exclusive discussions currently ongoing.
For more on $FUM #FUM see: https://www.trinitydelta.org/companies/futura-medical/

Clinical data for @scancellpharma should demo value of core therapeutic vaccine techs #ImmunoBody & #Moditope; Modi-1 Ph I/II now underway. Earlier #GlyMab & #AvidiMab antibody platforms also hold promise. For more on #SCLP $SCLP see our Outlook note:
https://www.trinitydelta.org/companies/scancell/

FY22 guidance of 22-25% core revenue growth & SPL revenue c$4m. @MaxCyte_info likely to see sig revenue step up from 2023+ given a higher no of potential trigger events & later stage milestones (larger potential $ amounts). Read our post-FY21 $MXCT Update: https://www.trinitydelta.org/companies/maxcyte/

Diagnostic capabilities and infrastructure of @AvactaDx established. Therapeutics newsflow, notably related to lead asset #AVA6000, provides multiple value-inflection points for @avacta. For more on #AVCT $AVCT see our post FY21 Update note: https://www.trinitydelta.org/companies/avacta/